Celltrion Inc. and Alteogen Inc. paced a sharp Kosdaq retreat Friday, dragging the growth-oriented index down 3.2 percent by the close as a U.S. biotech rout spilled into Seoul and local funds trimmed positions ahead of a long diplomatic week centered on APEC.
Session mechanics
The Korea Exchange said Kosdaq turnover rose 18 percent from Thursday even though the main Kospi also finished lower. Biotech and platform drug developers accounted for more than half of the index’s point loss, a reversal from earlier in the week when contract research names rallied on export order data.
Celltrion, which has expanded biosimilar sales in Europe and the United States, fell more than 4 percent. Alteogen, known for its long-acting drug delivery technology licensed to global pharma partners, dropped nearly 6 percent after U.S. peer indices logged their steepest one-day decline since midsummer.
U.S. spillover
Overnight, the Nasdaq Biotechnology Index shed more than 2 percent as investors questioned whether GLP-1 supply agreements and oncology trial readouts justified recent multiples. Korean funds with mandate overlap often adjust Kosdaq biotech baskets in the morning session when U.S. futures signal a risk-off tone.
Currency moves added friction. The won weakened past 1,420 per dollar during Seoul trading, raising the local cost of U.S. licensing payments for companies like Alteogen that book royalty in dollars while paying researchers in won.
Celltrion’s dual narrative
Celltrion continues to benefit from steady biosimilar infusions in hospital channels, but traders said Friday’s move reflected positioning rather than fundamentals. The company’s third-quarter preview, expected next week, will focus on whether U.S. inventory normalization is complete after wholesalers worked down pandemic-era stockpiles.
Some offshore funds used the weakness to add exposure, according to block-desk chatter, betting that Korea’s biotech complex will decouple once APEC-related travel restrictions clear and investor roadshows resume in Gyeongju and Seoul.
Alteogen and the platform trade
Alteogen’s pipeline includes technology transfers that turn injectable biologics into longer-lasting formulations. Partners in the United States and Europe have highlighted the platform in earnings calls, but Korean retail investors treat the stock as a high-beta proxy for U.S. risk appetite.
Analysts at Kiwoom Securities noted that Alteogen’s royalty stream is back-end loaded; near-term earnings depend on milestone payments that can shift quarter to quarter. That structure magnifies swings when global growth scares hit.
What Monday may bring
With the Kospi closed for the weekend, Kosdaq traders will watch U.S. futures Sunday night and any APEC-related policy headlines from the presidential office. Biotech names historically rebound quickly when memory and chip stocks stabilize, because foreign investors bucket them as Korea’s “innovation” sleeve.
Until then, Friday’s session is a reminder that Kosdaq remains a pressure valve for global risk—not an insulated playground for domestic story stocks.
Broader Kosdaq context
Outside biotech, Kosdaq software and game developers finished mixed, showing that the board is not uniformly weak. However, exchange data showed net selling by retail margin traders concentrated in names with price-to-sales ratios above 15, a pattern seen during prior U.S. rate scares. Institutional investors, meanwhile, added small positions in contract manufacturers tied to medical device exports, suggesting a barbell strategy rather than a wholesale exit from growth stocks.
Market strategists at Mirae Asset Securities said Monday’s opening will hinge on whether Samsung Electronics stabilizes after Friday’s slide. Historically, Kosdaq biotech does not recover until chip sentiment firms, because foreign allocators treat both as part of Korea’s “cyclical plus innovation” bundle in emerging-market portfolios.
Exchange data detail
Korea Exchange disclosures showed foreign investors net-sold 420 billion won of Kosdaq shares on Friday alone, the largest single-day outflow since August. Local pension funds were net buyers, but their orders were not large enough to offset hedge fund de-risking tied to U.S. futures. Trading halts were not triggered, yet volatility filters widened bid-ask spreads on mid-cap drug developers by roughly 8 percent compared with Thursday.
Derivatives desks reported increased put buying on Kosdaq 150 futures, a hedge against further biotech weakness if U.S. clinical trial disappointments continue next week. Retail investors on margin saw maintenance calls rise modestly, though brokerages said overall loan books remain healthy.